# An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

> **NCT07293754** · PHASE1,PHASE2 · RECRUITING · sponsor: **Repertoire Immune Medicines** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** RPTR-1-201
- **DRUG:** PD-1 / PD-L1 monoclonal antibody

## Key facts

- **NCT ID:** NCT07293754
- **Lead sponsor:** Repertoire Immune Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2028-12-15
- **Final completion:** 2029-04-15
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07293754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07293754, "An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07293754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*